Daniel Drucker (@danieljdrucker.bsky.social)

P2B 24 week data for the GCGR-GLP-1R co-agonist Pemvidutide #MASH resolution without worsening of fibrosis at 24 weeks but not fibrosis improvement without worsening of MASH www.thelancet.com/journals/lan...

loading . . .

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MAS... https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02114-2/abstract